Rebecca Taub
Founder, Director & Senior Scientific & Medical Advisor Madrigal Pharmaceuticals
Seminars
Thursday 17th September 2026
Adapting Mash Development Strategies Within An Evolving Treatment Landscape To Define Clinical Value, Enable Differentiation & Establish Future Standards Of Care
9:00 am
- Navigating the transition to a post-approval MASH landscape to address emerging clinical expectations and unmet patient needs, enabling more effective development planning and strengthening future therapeutic value
- Evaluating how emerging therapies, active comparators and future combination approaches will shape post-approval development pathways, enabling clearer differentiation and improving treatment integration strategies
- Designing late-stage clinical and registrational strategies around evolving standards of care to improve regulatory readiness, accelerating broader adoption and long-term patient impact
